Autoscribe Publishes White Paper on Risk Management For LIMS Projects
News Dec 28, 2012
Autoscribe, developer of the Matrix Gemini Laboratory Information Management System (LIMS), has published a white paper which looks at the common factors that contribute to risk in LIMS projects. Available for download from www.autoscribe.co.uk/about/press-releases/2012/146-risk-management, the white paper includes examples of projects that have run into difficulties due to inadequate risk management.
Autoscribe’s founder and CEO, John Boother, explains: “There are far too many LIMS projects that have collapsed or failed to deliver the expected benefits. Frequently projects end up significantly over budget with additional non-budgeted, on-going costs such as having IT consultants on site for many months after delivery of a system, because of inadequate planning.”
“Projects of this nature are typically characterised by a changed specification from that originally described, leading to system ‘configuration’ continuing sometimes for years after original system delivery”, he continued.. “We at Autoscribe believe that the key to a successful LIMS project is a clear understanding of the potential risks and the implementation of a structured program to mitigate these risks.”
The white paper looks at the risks associated with the various stages of a LIMS project. These include: project definition; evaluation and selection of the system; implementation and rollout and support and upgrade.
Linguamatics iScite 2.0 Wins Bio-IT World’s Best of Show Judges’ PrizeNews
Linguamatics today announced that Bio-IT World has awarded Linguamatics the Best of Show Judges’ Prize for Linguamatics iScite 2.0, a software-as-a-service AI scientific search application. iScite was one of 46 products considered for this prestigious award at last week’s Bio-IT World Conference & Expo in Boston.
Understanding Lung Cancer Cell Networks Helps Create Drug TreatmentsNews
A team of scientists has identified networks inside lung cancer cells that will help understand this cancer and fight it with drug treatments.READ MORE